Startup aims to churn out other orphan drug startups

04/25/2013 | Xconomy

Armed with $16 million in venture capital, former MedImmune boss David Mott's new enterprise Cydan will find and fund small firms with promising orphan drug candidates. Investor return will be through licensing deals with or acquisition by larger drugmakers. Mott plans to collaborate with parent and patient advocacy groups and will subcontract toxicology, pharmacology and other testing to reduce development risk.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY